Evidence map›Paper›PMID 41748316›Full record

ArticleCancer medicine2026

KIFC1 is Associated With Sarcomatoid Differentiation, Immune Response, and a Poor Prognosis in Clear Cell Renal Cell Carcinoma.

Yoshinori Nakano, Yohei Sekino, Go Kobayashi, Hikaru Nakahara, Shintaro Akabane, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yoshinori NakanoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-3026-976X
Yohei SekinoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-1525-5463
Go KobayashiLaboratory of Molecular Pathology, Department of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima, Japan.
Hikaru NakaharaDepartment of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
Shintaro AkabaneDepartment of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kenshiro TakemotoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-9077-4733
Miki NaitoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-3485-0751
Shunsuke MiyamotoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0001-8397-115X
Kohei KobatakeDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-2098-3916
Hiroyuki KitanoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0003-2223-2403
Keisuke GotoDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Akihiro GorikiDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Keisuke HiedaDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takao HinoiDepartment of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
Nobuyuki HinataDepartment of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID https://orcid.org/0000-0001-7014-6812

Funding

Japan Society for the Promotion of Science 19K18586
6 · The paper itself

Abstract

introductionCentrosome clustering is a cancer-specific adaptation that allows cells with centrosome amplification to evade mitotic catastrophe and has emerged as a potential therapeutic target. We analyzed the prognostic role of several molecules related to centrosome clustering and found that Kinesin Family Member C1 (KIFC1) was strongly associated with a poor prognosis. KIFC1, a kinesin motor protein, plays a central role in centrosome clustering. However, its biological and clinical significance in clear cell renal cell carcinoma (ccRCC) remains poorly understood.

methodsWe conducted a comprehensive analysis using several public datasets (TCGA KIRC, JAVELIN101, IMmotion151, and others) and a Hiroshima ccRCC cohort (n = 110) to evaluate the expression of KIFC1, clinicopathological associations, the prognosis, and treatment response. Gene Set Enrichment Analysis was performed to explore associated pathways.

resultsImmunohistochemical and in silico analyses showed that high KIFC1 expression was significantly associated with high tumor grade, advanced TNM stage, and sarcomatoid differentiation. A multivariate analysis demonstrated that the high-expression of KIFC1 was independently associated with poor overall survival. Gene Set Enrichment Analysis revealed enrichment of epithelial-mesenchymal transition and interferon gamma response pathways in KIFC1-high tumors. The expression of KIFC1 was also correlated with TKI resistance, immune response, high clonal neoantigen load, and BAP1 mutation.

conclusionKIFC1 serves as a multifunctional molecule linking epithelial-mesenchymal transition, immune modulation, and treatment resistance. It may be a promising prognostic biomarker and therapeutic target in ccRCC, warranting further functional and clinical investigation.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellKidney NeoplasmsKinesinsCell DifferentiationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorKIFC1 protein, humanKinesinscentrosome clusteringepithelial–mesenchymal transitionimmune responseKIFC1renal cell carcinoma

Identifiers

PMID41748316
PMCPMC12945555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.